Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 28:8:422.
doi: 10.3389/fphar.2017.00422. eCollection 2017.

An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol

Paula Morales  1 , Patricia H Reggio  1 , Nadine Jagerovic  2
Affiliations
Review

An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol

Paula Morales et al. Front Pharmacol. .

Abstract

Cannabidiol (CBD) has been traditionally used in Cannabis-based preparation, however historically, it has received far less interest as a single drug than the other components of Cannabis. Currently, CBD generates considerable interest due to its beneficial neuroprotective, antiepileptic, anxiolytic, antipsychotic, and anti-inflammatory properties. Therefore, the CBD scaffold becomes of increasing interest for medicinal chemists. This review provides an overview of the chemical structure of natural and synthetic CBD derivatives including the molecular targets associated with these compounds. A clear identification of their biological targets has been shown to be still very challenging.

Keywords: cannabidiol; cannabidiol derivative; cannabinoid receptor; molecular target; therapeutic application.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Cannabidiol (CBD) and (–)-trans-Δ9–tetrahydrocannabinol (Δ9–THC).
FIGURE 2
FIGURE 2
Natural phytocannabinoid CBD analogs.
FIGURE 3
FIGURE 3
Aromatic analogs of CBD.
FIGURE 4
FIGURE 4
Selected metabolites of CBD.
FIGURE 5
FIGURE 5
Cannabidiol (CBD)-related Machaerium multiflorum, Rhododendron ferrugineum L. and, Lindera umbellata Thunb. compounds.
FIGURE 6
FIGURE 6
(+)-CBD and hydrogenated CBD derivatives.
FIGURE 7
FIGURE 7
Dimethylheptyl (DMH)-CBD derivatives.
FIGURE 8
FIGURE 8
Cannabidiol analogs modified on the C4′-alkyl chain.
FIGURE 9
FIGURE 9
Chlorinated, brominated, and iodinated CBD derivatives.
FIGURE 10
FIGURE 10
Fluorinated CBD derivatives.
FIGURE 11
FIGURE 11
Cannabidiol derivatives modified at the hydroxyl groups.
FIGURE 12
FIGURE 12
Diacetylated-CBD analogs.
FIGURE 13
FIGURE 13
Quinones related to CBD.
FIGURE 14
FIGURE 14
Miscellaneous CBD derivatives.
See this image and copyright information in PMC

References

    1. Ahrens J., Demir R., Leuwer M., De La Roche J., Krampfl K., Foadi N., et al. (2009). The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-beta glycine receptor function. Pharmacology 83 217–222. 10.1159/000201556 - DOI - PubMed
    1. Aizpurua-Olaizola O., Soydaner U., Öztürk E., Schibano D., Simsir Y., Navarro P., et al. (2016). Evolution of the cannabinoid and terpene content during the growth of cannabis sativa plants from different chemotypes. J. Nat. Prod. 79 324–331. 10.1021/acs.jnatprod.5b00949 - DOI - PubMed
    1. Anavi-Goffer S., Baillie G., Irving A. J., Gertsch J., Greig I. R., Pertwee R. G., et al. (2012). Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J. Biol. Chem. 287 91–104. 10.1074/jbc.M111.296020 - DOI - PMC - PubMed
    1. Appendino G., Cabello de Alba M. L. B., Munoz Blanco E. (2015). Preparation of novel cannabidiol quinone derivatives as PPARγ agonists. International Patent No WO2015/158381 Washington, DC.
    1. Appendino G., Gibbons S., Giana A., Pagani A., Grassi G., Stavri M., et al. (2008). Antibacterial Cannabinoids from Cannabis sativa : a structure-activity study. J. Nat. Prod. 71 1427–1430. 10.1021/np8002673 - DOI - PubMed